The observation of lower PER2 mRNA levels in cell lines of metastatic origin suggests that reduced PER2 gene expression may contribute to the acquisition of aggressive phenotype and drug resistance in HCC. This evidence concerns the gene PER2 and hepatocellular carcinoma.